The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. The decision follows a supplemental application from Eisai, which is codeveloping Leqembi with Biogen, based on the modeling of data from the Phase…
Read more
“I’ve never been so cold in my life.” I recently visited Washington, D.C., and it was cold — perhaps not by the standards of northern states, but bitter compared with my home in South Florida. Now, I’ve been colder in my life, but the quotation above pumped through my mind…
Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company recently announced results from two Phase 3 trials testing AXS-05. One study, ACCORD-2, hit its…
Becoming educated and informed about Alzheimer’s is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your Alzheimer’s journey.
There is no cure for Alzheimer’s yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
